Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system Keith A. Sharkey, Nissar A. Darmani, and Linda A. Parker European Journal of Pharmacology, 2014 January 5; 722. doi : 10.1016/j.ejphar.2013.09.068. Abstract Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances. However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently observed as side-effects of a variety of medications, notably those used to treat cancer. Cannabis has long been known to limit or prevent nausea and vomiting from a variety of causes.This has [...]
Lire la suiteIsolation of a High Affinity Cannabinoid for Human CB1 Receptor from a Medicinal Cannabis Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol Pasquale Linciano, Cinzia Citti, Livio Luongo, Carmela Belardo, Sabatino Maione, Maria Angela Vandelli, Flavio Forni, Giuseppe Gigli, Aldo Laganà, Carmela Maria Montone, Giuseppe Cannazza Journal of Natural Products, 2019 Dec 31. doi: 10.1021/acs.jnatprod.9b00876. Abstract The butyl homologues of Δ9-tetrahydrocannabinol, Δ9-tetrahydrocannabutol (Δ9-THCB), and cannabidiol, cannabidibutol (CBDB), were isolated from a medicinal Cannabis sativa variety (FM2) inflorescence. Appropriate spectroscopic and spectrometric characterization, including NMR, UV, IR, ECD, and HRMS, was carried out on both cannabinoids. The chemical structures and absolute configurations of the isolated cannabinoids were [...]
Lire la suited-Lysergic acid diethylamide has major potential as a cognitive enhancer Felipe Augusto Cini, Isis Ornelas, Encarni Marcos, Livia Goto-Silva, Juliana Nascimento, Sergio Ruschi, José Salerno, Karina Karmirian, Marcelo Costa, Eduardo Sequerra, Dráulio de Araújo, Luis Fernando Tófoli, César Rennó-Costa, Daniel Martins-de-Souza, Amanda Feilding, Stevens Rehen, Sidarta Ribeiro BioRxiv, 6 december 2019. Doi : 10.1101/866814 Abstract Psychedelic agonists of serotonin receptors induce neural plasticity and synaptogenesis, but their potential to enhance learning remains uncharted. Here we show that a single dose of d-LSD, a potent serotonergic agonist, increased novel object preference in young and adult rats several days after treatment. d- LSD alone did not increase preference [...]
Lire la suitePsilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010 Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]
Lire la suiteLong-term use of psychedelic drugs is associated with differences in brain structure and personality in humans José Carlos Bouso, FernandaPalhano-Fontes, Antoni Rodríguez-Fornells, Sidarta Ribeiro, Rafael Sanches, José Alexandre S. Crippa, Jaime E.C. Hallak, Draulio B. de Araujo, Jordi Riba European Neuropsychopharmacology, 2015, 25, 483–492 http://dx.doi.org/10.1016/j.euroneuro.2015.01.008 Abstract Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception,emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that psychedelic 5-hydroxytryptamine (5HT)2A [...]
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : Pharmacologie, Neurophysiologie, Psychologie, Dr Christian SUEUR, GRECC, décembre 2019 Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, Culture, Spiritualité, Chamanisme Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca….
Lire la suiteThe mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity Rainer Kraehenmann, André Schmidt, Karl Friston, Katrin H. Preller, Erich Seifritz, Franz X. Vollenweider NeuroImage : Clinical, 2016, 11, 53–60 http://dx.doi.org/10.1016/j.nicl.2015.08.009 a b s t r a c t Stimulation of serotonergic neurotransmission by psilocybin has been shown to shift emotional biases away from negative towards positive stimuli. We have recently shown that reduced amygdala activity during threat processing might underlie psilocybin's effect on emotional processing. However, it is still not known whether psilocybin modulates bottom-up or top-down connectivity within the visual-limbic-prefrontal network underlying threat processing.We therefore analyzed our previous fMRI data using [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, October 2019, Volume 10, Article 1145 doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suiteStudy protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease progression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial Berzenn Urbi, Simon Broadley, Richard Bedlack, Ethan Russo, Arman Sabet British Medical Journal Open, 2019, 9, e029449. doi : 10.1136/bmjopen-2019-029449 Abstract Introduction : Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy [...]
Lire la suiteProlonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users Camilla Beale, Samantha J. Broyd, Yann Chye, Chao Suo, Mark Schira, Peter Galettis, Jennifer H. Martin, Murat Yücel and Nadia Solowij Cannabis and Cannabinoid Research, 2018, 3, 1, 94-107. Doi : 10.1089/can.2017.0047 Abstract Introduction : Chronic cannabis use is associated with neuroanatomical alterations in the hippocampus. While adverse impacts of cannabis use are generally attributed to D9 tetrahydro-cannabinol, emerging naturalistic evidence suggests cannabidiol (CBD) is neuroprotective and may ameliorate brain harms associated with cannabis use, including protection from hippocampal volume loss. This study examined whether prolonged administration of CBD to regular cannabis users [...]
Lire la suite